Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf MedicamentfiledCriticalPf Medicament
Publication of CO6390002A2publicationCriticalpatent/CO6390002A2/en
La presente invención se refiere a un anticuerpo aislado nuevo, o a los compuestos derivados o fragmentos funcionales del mismo, capaz de unirse a CXCR4 pero también inducir cambios conformacionales de los homodímeros y/o heterodímeros CXCR4.Más particularmente, la presente invención se refiere a los anticuerpos 414H5 y 515H7, específicos frente a la proteína CXCR4, así como a su utilización para el tratamiento del cáncer. También se cubren composiciones farmacéuticas compuestas por dichos anticuerpos y un procedimiento para la selección de dichos anticuerpos.The present invention relates to a novel isolated antibody, or to derivative compounds or functional fragments thereof, capable of binding to CXCR4 but also inducing conformational changes of CXCR4 homodimers and / or heterodimers. More particularly, the present invention relates to 414H5 and 515H7 antibodies, specific against the CXCR4 protein, as well as its use for the treatment of cancer. Also covered are pharmaceutical compositions composed of said antibodies and a method for the selection of said antibodies.
CO11042011A2008-10-012011-04-05
NEW ANTI-CXCR4 ANTIBODIES AND ITS USE FOR CANCER TREATMENT
CO6390002A2
(en)
Substituted 2-amino-acetamide derived compounds; pharmaceutical composition; Useful in the treatment of lung diseases, rheumatic disease, autoimmune disease, among others.